N. Cheung

发表

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody

S. Chandarlapaty, Y. Janjigian, E. de Stanchina, 2017, Oncoimmunology.

ABP-100: A tetravalent bispecific T-cell engaging antibody for HER2+ solid tumors.

G. MacBeath, N. Cheung, A. Boudot, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study

I. Ostrovnaya, K. Hsu, D. Goldman, 2018, Oncoimmunology.

A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long‐term progression‐free survival of patients with resistant neuroblastoma

S. Roberts, O. Becher, B. Kushner, 2017, International journal of cancer.

Sialyltransferase STX (ST8SiaII): A novel molecular marker of metastatic neuroblastoma

A. Vickers, N. Cheung, I. Cheung, 2006, International journal of cancer.

Measuring circulating neuroblastoma cells by quantitative reverse transcriptase–polymerase chain reaction analysis

N. Cheung, I. Cheung, A. Sahota, 2004, Cancer.

Evolving significance of prognostic markers associated with treatment improvement in patients with Stage 4 neuroblastoma

W. Gerald, J. Mora, J. Qin, 2002, Cancer.

Neuroblastoma metastatic to the central nervous system

G. Heller, B. Kushner, K. Kramer, 2001, Cancer.

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma

N. Cheung, Jeong A. Park, 2020, Journal of Hematology & Oncology.

T cell engaging bispecific antibody (T‐BsAb): From technology to therapeutics

N. Cheung, Z. Wu, Z. Wu, 2017, Pharmacology & therapeutics.

Imaging , Diagnosis , Prognosis KIR and HLA Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma

K. Hsu, B. Dupont, Junting Zheng, 2009 .

KIR and HLA Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma

K. Hsu, B. Dupont, Junting Zheng, 2009, Clinical Cancer Research.

Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies

N. Cheung, Jeong A. Park, 2022, Journal for ImmunoTherapy of Cancer.

Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies

N. Cheung, Jeong A. Park, 2021, Journal for ImmunoTherapy of Cancer.

Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes

M. Sadelain, J. Latouche, Hong-fen Guo, 1998, The Journal of experimental medicine.

Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential

Mahiuddin Ahmed, Hong-fen Guo, N. Cheung, 2015, Leukemia.

Cancer Immunotherapy Principles and Practice

Ke Liu, Pedro Romero, Patricia A. Young, 2018 .

Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology

K. Curran, N. Cheung, Maya Suzuki, 2015, Pediatric blood & cancer.

Disialoganglioside GD2 as a therapeutic target for human diseases

N. Cheung, Maya Suzuki, 2015, Expert opinion on therapeutic targets.

Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response

Linlin Wang, N. Cheung, Jeong A. Park, 2021, Journal of Hematology & Oncology.

Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis

S. Larson, G. Nash, A. Cercek, 2021, Molecular Cancer Therapeutics.

Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release

Hong Xu, L. Lum, N. Cheung, 2021, Journal for ImmunoTherapy of Cancer.

Monoclonal antibody therapies for solid tumors

N. Cheung, D. Tassev, 2009, Expert opinion on biological therapy.

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2

D. Pankov, N. Cheung, S. S. Hoseini, 2017, Oncoimmunology.

Potent antitumor effect of T cells armed with anti‐GD2 bispecific antibody

Hong Xu, Hong-fen Guo, N. Cheung, 2021, Pediatric blood & cancer.

GD2-targeted immunotherapy and radioimmunotherapy.

N. Cheung, K. Dobrenkov, 2014, Seminars in oncology.

Therapeutic Antibodies and Immunologic Conjugates

N. Cheung, 2020, Abeloff's Clinical Oncology.

Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors

M. Huse, M. Cheng, Mahiuddin Ahmed, 2016, Oncoimmunology.

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.

K. Hsu, G. Heller, Junting Zheng, 2012, The Journal of clinical investigation.

KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.

J. Boudreau, K. Hsu, G. Heller, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Structural design of disialoganglioside GD2 and CD3‐bispecific antibodies to redirect T cells for tumor therapy

M. Cheng, Mahiuddin Ahmed, Hong Xu, 2015, International journal of cancer.

Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies

A. Vickers, S. Modak, N. Cheung, 2002, Cancer Immunology, Immunotherapy.

Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo

Hong-fen Guo, N. Cheung, I. Cheung, 2012, Oncoimmunology.

Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma.

G. Heller, N. Cheung, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Monoclonal antibody-based therapy for neuroblastoma

N. Cheung, 2000, Current oncology reports.

Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas

C. Cordon-Cardo, Helena R. Chang, A. Houghton, 1992, Cancer.

Bispecific antibodies for the treatment of neuroblastoma.

N. Cheung, Madelyn Espinosa-Cotton, 2022, Pharmacology & therapeutics.

Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor.

W. Gerald, S. Modak, N. Cheung, 2002, Medical and pediatric oncology.

B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study.

Jason S. Lewis, J. Carrasquillo, M. LaQuaglia, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reducing Epitope Spread during Affinity Maturation of an Anti-Ganglioside GD2 Antibody1

Xiaodong Huang, D. Bundle, Chang-Chun Ling, 2009, The Journal of Immunology.

A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy

Hong Xu, Hong-fen Guo, N. Cheung, 2021, Oncoimmunology.

Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells

S. Ferrone, C. Tsao, J. Hsu, 2015, Oncoimmunology.

Methionine depletion with recombinant methioninase: In vitro and in vivo efficacy against neuroblastoma and its synergism with chemotherapeutic drugs

N. Cheung, Jian Hu, 2009, International journal of cancer.

Antibody Maturation of an Anti-Ganglioside GD 2 Reducing Epitope Spread during Affinity Bundle

Xiaodong Huang, D. Bundle, Chang-Chun Ling, 2009 .

Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8

S. Larson, M. Rosenblum, G. Heller, 1993, Journal of Neuro-Oncology.

Anti-Idiotype Immunotherapy Strategies for Brain Tumors

N. Cheung, 2001 .

A novel O‐acetylated ganglioside detected by anti‐GD2 monoclonal antibodies

N. Cheung, Jiannan Ye, Jian Nan Ye, 1992, International journal of cancer.

Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma.

W. Gerald, J. Mora, N. Cheung, 2003, Cancer letters.

Pretargeting: A Path Forward for Radioimmunotherapy

S. Larson, S. Cheal, N. Cheung, 2022, The Journal of Nuclear Medicine.

Clonal evolution during metastatic spread in high-risk neuroblastoma

C. Iacobuzio-Donahue, E. Papaemmanuil, G. Gundem, 2022, bioRxiv.

Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells

N. Lue, N. Cheung, E. Yu, 2022, Journal of Hematology & Oncology.

KMT2A‐MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8‐year follow‐up

Marilyn M. Li, E. Rappaport, B. Gregory, 2021, Pediatric blood & cancer.

Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors

N. Cheung, P. Basse, M. Barmada, 2000, Cancer Immunology, Immunotherapy.

Malignant pheochromocytoma: current status and initiatives for future progress.

David I. Smith, L. Greene, A. Tischler, 2004, Endocrine-related cancer.

Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma with Prior Disease Progression.

Yi Feng, S. Roberts, A. Mauguen, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose‐intensive use of cyclophosphamide in ablation of neuroblastoma

M. LaQuaglia, B. Kushner, N. Cheung, 1990, Cancer.

GD 20 ligosaecharide : Target for Cytotoxic T Lymphocytes

N. Cheung, B. Zhao, 2003 .

A quantitative enzyme-linked immunosorbent assay for honeybee venom-specific immunoglobulin G.

N. Cheung, M. Reid, J. M. Kwasnicki, 1982, The Journal of allergy and clinical immunology.

Title>Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells

H. Juhl, E. Petrella, N. Cheung, 1997 .

Induction of tumor cell death by anti-GD2 monoclonal antibodies (MoAb): Requirement of antibody Fc and a long residence time (slow koff)

N. Cheung, J. Hu, H. Xu, 2007 .

Autologous bone marrow transplantation in children with advanced neuroblastoma

H. Mugishima, M. Kaneko, Y. Tsuchida, 1994, Cancer.

Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies

J. Humm, S. Larson, M. Souweidane, 2022, Journal of Hematology & Oncology.

Quantitation of GD2 synthase mRNA by real‐time reverse transcription‐polymerase chain reaction

B. Kushner, N. Cheung, N. Collins, 2002, Cancer.

Human Cytomegalovirus Infection Promotes Expansion of a Functionally Superior Cytoplasmic CD3+ NK Cell Subset with a Bcl11b-Regulated T Cell Signature

Joseph C. Sun, K. Hsu, T. Mertens, 2021, The Journal of Immunology.

Immunotherapy with anti‐GD2 monoclonal antibody in infants with high‐risk neuroblastoma

S. Roberts, B. Kushner, K. Kramer, 2022, International journal of cancer.

Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.

I. Ostrovnaya, D. Kuk, N. Cheung, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins

Kazuro Furukawa, K. Honke, K. Furukawa, 2021, International journal of molecular sciences.

Kinetics of primary tumor regression with chemotherapy: Implications for the timing of surgery

W. Gerald, N. Cheung, M. Quaglia, 1996, Annals of Surgical Oncology.

Engineering anti‐GD2 monoclonal antibodies for cancer immunotherapy

Mahiuddin Ahmed, N. Cheung, 2014, FEBS letters.

Targets and Antibody Formats for Immunotherapy of Neuroblastoma

N. Cheung, Jeong A. Park, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor

N. Cheung, Madelyn Espinosa-Cotton, 2021, Frontiers in Oncology.

Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.

N. Cheung, S. S. Hoseini, 2017, Cancer letters.

Major histocompatibility proteins, anti‐Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer

M. Rosenblum, N. Cheung, J. Dalmau, 1995, Cancer.

Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody, 3F8

G. Heller, N. Cheung, M. Barmada, 1999, International journal of cancer.

Long‐term complications in survivors of advanced stage neuroblastoma

K. Ness, C. Sklar, J. Gurney, 2005, Pediatric blood & cancer.

Mechanism by Which Orally Administered β-1,3-Glucans Enhance the Tumoricidal Activity of Antitumor Monoclonal Antibodies in Murine Tumor Models1

Jun Yan, G. Ostroff, Jun Yan, 2004, The Journal of Immunology.

Cancer immunotherapy via targeted TGF-β signalling blockade in TH cells

Ming O. Li, Peng Li, Hong Xu, 2020, Nature.

Cancer immunotherapy via targeted TGF-β signalling blockade in TH cells

Ming O. Li, Ming Liu, Peng Li, 2020, Nature.

Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.

N. Cheung, Jeong A. Park, 2017, Cancer treatment reviews.

Immunotherapy of Childhood Sarcomas

S. Roberts, A. Chou, N. Cheung, 2015, Front. Oncol..

Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations

Heather L. Mulder, Samuel W. Brady, Michael C. Rusch, 2020, Nature Communications.

Ototoxicity from high‐dose use of platinum compounds in patients with neuroblastoma

N. Cheung, B. Kushner, A. Budnick, 2006, Cancer.

Differential Impact of ALK Mutations in Neuroblastoma

N. Shukla, N. Bouvier, S. Roberts, 2021, JCO precision oncology.

ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures.

Sara M. Federico, M. Fowkes, J. Maris, 2019, Cancer cell.

Treatment and outcome of adult‐onset neuroblastoma

M. LaQuaglia, S. Wolden, S. Roberts, 2018, International journal of cancer.

Striking dichotomy in outcome of MYCN‐amplified neuroblastoma in the contemporary era

N. Cheung, M. LaQuaglia, S. Roberts, 2014, Cancer.

Recurrent pre‐existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases

Irina Ostrovnaya, I. Ostrovnaya, S. Tickoo, 2013, Genes, chromosomes & cancer.

Chronic neuroblastoma

N. Cheung, B. Kushner, K. Kramer, 2002, Cancer.

Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies

N. Cheung, D. Casey, 2020, Cancer Immunology Research.

Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma

N. Cheung, D. Casey, Tsung-Yi Lin, 2019, Front. Oncol..

Targeted drug distribution in tumor extracellular fluid of GD2‐expressing neuroblastoma patient‐derived xenografts using SN‐38‐loaded nanoparticles conjugated to the monoclonal antibody 3F8

J. Mora, C. Lavarino, N. Cheung, 2017, Journal of controlled release : official journal of the Controlled Release Society.

Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study

N. Cheung, S. Roberts, B. Kushner, 2017, Pediatric blood & cancer.

Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults

I. Ostrovnaya, N. Cheung, Jessie W Gu, 2016, Pediatric blood & cancer.

Osteochondroma in long‐term survivors of high‐risk neuroblastoma

I. Ostrovnaya, N. Cheung, D. Kuk, 2015, Cancer.

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study

I. Ostrovnaya, D. Kuk, B. Kushner, 2015, Oncoimmunology.

Antibody induced pain in children: An opportunity to study pain mechanism, IgG design and analgesics

N. Cheung, 2015, Pediatric blood & cancer.

Alteration of electrostatic surface potential enhances affinity and tumor killing properties of anti-ganglioside GD2 monoclonal antibody hu3F8

Mahiuddin Ahmed, Hong-fen Guo, N. Cheung, 2015 .

Key role for myeloid cells: Phase II results of anti‐GD2 antibody 3F8 plus granulocyte‐macrophage colony‐stimulating factor for chemoresistant osteomedullary neuroblastoma

I. Ostrovnaya, N. Cheung, D. Kuk, 2014, International journal of cancer.

Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti‐GD2 3F8 monoclonal antibody

S. Roberts, B. Kushner, K. Kramer, 2013, Cancer.

In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors

Y. Goldgur, Mahiuddin Ahmed, Hong-fen Guo, 2013, PloS one.

Reply to L. Moreno et al.

I. Ostrovnaya, B. Kushner, N. Cheung, 2013, Journal of Clinical Oncology.

Anti‐CD3 × anti‐GD2 bispecific antibody redirects T‐cell cytolytic activity to neuroblastoma targets

N. Cheung, A. Thakur, L. Lum, 2012, Pediatric blood & cancer.

Plerixafor plus granulocyte‐colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma

N. Cheung, B. Kushner, K. Kramer, 2012, Pediatric blood & cancer.

Hypothyroidism after 131I‐monoclonal antibody treatment of neuroblastoma

S. Larson, C. Sklar, N. Cheung, 2010, Pediatric blood & cancer.

Reduced risk of secondary leukemia with fewer cycles of dose‐intensive induction chemotherapy in patients with neuroblastoma

L. Qin, S. Jhanwar, B. Kushner, 2009, Pediatric blood & cancer.

Induction for high‐risk neuroblastoma

N. Cheung, B. Kushner, N. Cheung, 2007, Pediatric blood & cancer.

High‐dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: Broad implications for immunotherapy

N. Cheung, B. Kushner, K. Kramer, 2007, Pediatric blood & cancer.

Liver involvement in neuroblastoma: The memorial Sloan‐Kettering experience supports treatment reduction in young patients

N. Cheung, M. LaQuaglia, B. Kushner, 2006, Pediatric blood & cancer.

Reciprocal impacts of telomerase activity and ADRN/MES differentiation state in neuroblastoma tumor biology

X. Zhou, N. Lue, N. Cheung, 2021, Communications Biology.

Reciprocal impacts of telomerase activity and tumor cell differentiation in neuroblastoma tumor biology

X. Zhou, N. Lue, N. Cheung, 2021, bioRxiv.

Prognostic value of MYCN and ID2 overexpression in neuroblastoma

W. Gerald, N. Cheung, M. Alaminos, 2005, Pediatric blood & cancer.

MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors.

Hong Xu, Hong-fen Guo, N. Cheung, 2009, Cancer research.

MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas

W. Gerald, S. Tickoo, R. Blasberg, 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy

Hong-fen Guo, N. Cheung, Jeong A. Park, 2021, Journal for ImmunoTherapy of Cancer.

Insulin and glucose homeostasis in childhood cancer survivors treated with abdominal radiation: A pilot study.

C. Sklar, C. Moskowitz, K. Oeffinger, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Skeletal muscle metastases in neuroblastoma share common progenitors with primary tumor and biologically resemble stage MS disease

G. Gundem, S. Roberts, A. Price, 2023, Frontiers in Oncology.

Small molecule nerve growth factor analogs image receptors in vivo

N. Cheung, R. Lisbona, L. Lesauteur, 1996, Nature Biotechnology.

High‐dose melphalan with 6‐hydroxydopamine–purged autologous bone marrow transplantation for poor‐risk neuroblastoma

B. Kushner, N. Cheung, R. O'reilly, 1991, Cancer.

Treatment reduction for neuroblastoma

N. Cheung, B. Kushner, N. Cheung, 2004, Pediatric blood & cancer.

A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy

T. Akhurst, N. Cheung, B. Kushner, 2009, Pediatric blood & cancer.

Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease

W. Gerald, J. Mora, N. Cheung, 2001, Cancer.

Checkpoint kinase inhibitor synergizes with DNA‐damaging agents in G1 checkpoint‐defective neuroblastoma

Hong Xu, Hoa Tran, N. Cheung, 2011, International journal of cancer.

Five‐day courses of irinotecan as palliative therapy for patients with neuroblastoma

N. Cheung, B. Kushner, K. Kramer, 2005, Cancer.

Differential impact of high‐dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma

L. Qin, N. Cheung, B. Kushner, 2010, Cancer.

Disialoganglioside GD2 anti‐idiotypic monoclonal antibodies

N. Cheung, A. Cañete, N. Cheung, 1993, International journal of cancer.

GD2 synthase

N. Cheung, N. Cheung, I. Cheung, 2001, Cancer.

Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: Possible leukemogenic role of temozolomide

N. Cheung, M. LaQuaglia, B. Kushner, 2008, Pediatric blood & cancer.

Autoantigen diversity in the opsoclonus‐myoclonus syndrome

M. Rosenfeld, J. Dalmau, F. Graus, 2003, Annals of neurology.

Antibody-independent phagocytosis of tumor cells by human monocyte-derived macrophages cultured in recombinant macrophage colony-stimulating factor

D. Munn, N. Cheung, 1995, Cancer Immunology, Immunotherapy.

T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia

Yi Feng, Hong Xu, Hong-fen Guo, 2021, Journal for ImmunoTherapy of Cancer.

Ifosfamide, carboplatin, and etoposide for neuroblastoma

N. Cheung, S. Roberts, B. Kushner, 2013, Cancer.

Desmoplastic small round cell tumor cancer stem cell-like cells resist chemotherapy but remain dependent on the EWSR1-WT1 oncoprotein

M. Ladanyi, R. Somwar, Hong-Jun Kang, 2022, Frontiers in Cell and Developmental Biology.

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody

S. Monette, Hong-fen Guo, N. Cheung, 2023, Journal for ImmunoTherapy of Cancer.

Radioimmunoassays for specific human IgG4

N. Cheung, 1983, Clinical reviews in allergy.

Lack of early bevacizumab‐related skeletal radiographic changes in children with neuroblastoma

N. Cheung, A. Price, S. Modak, 2009, Pediatric blood & cancer.

Targeting of Ganglioside GD2Monoclonal Antibody to Neuroblastoma

N. Cheung, J. Neely, B. Landmeier, 2006 .

Antibody-based diagnostic and therapeutic innovations for human cancer

K. Kramer, N. Cheung, 2001, Comprehensive therapy.

A dual‐specific anti‐IGF‐1/IGF‐2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma

D. Dimitrov, Qi Zhao, Hoa Tran, 2015, International journal of cancer.

Identification of immunotherapy and radioimmunotherapy targets on desmoplastic small round cell tumors

S. Tickoo, Hong-fen Guo, N. Cheung, 2023, Frontiers in Oncology.

Structure Based Refinement of a Humanized Monoclonal Antibody That Targets Tumor Antigen Disialoganglioside GD2

Mahiuddin Ahmed, N. Cheung, Jian Hu, 2014, Front. Immunol..

A rat model of leptomeningeal human neoplastic xenografts

N. Cheung, M. Ahdab-Barmada, S. Kemp, 1997, Journal of Neuro-Oncology.

Deep MicroRNA sequencing reveals downregulation of miR‐29a in neuroblastoma central nervous system metastasis

T. Tuschl, I. Ostrovnaya, T. Farazi, 2014, Genes, chromosomes & cancer.

CGTAAA CT scagoag TCEgert GAACTGSA argccregg gTTAGTG AAATTC TGCAAggc TCTGGCTA ACTTACA GTCATIT GcGcGTc. AGAccessa Tr:ACAT TICGGAcco casa.Agrico TracAg Aegrirceo A AGACCGAEG TGGAAGTGT

N. Cheung, 2017 .

Growth in a Rat Model of Human Neuroblastoma Decay-accelerating Factor Expression and Enhances Tumor CD 59 Expressed on a Tumor Cell Surface Modulates

T. Caragine, S. Tomlinson, N. Cheung, 2000 .

Transient sialoadenitis: A complication of 131I‐metaiodobenzylguanidine therapy

S. Larson, N. Cheung, P. Smith-Jones, 2008, Pediatric blood & cancer.

Efficacy of HER2-Targeted Intraperitoneal 225Ac α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis

S. Larson, M. McDevitt, G. Nash, 2023, The Journal of Nuclear Medicine.

Clinical outcomes of pediatric patients receiving multimodality treatment of second central nervous system relapse of neuroblastoma

S. Wolden, N. Pandit-Taskar, K. Tringale, 2022, Pediatric blood & cancer.

Small-molecule ligands of GD2 ganglioside, designed from NMR studies, exhibit induced-fit binding and bioactivity.

E. Purisima, K. Gehring, J. Blankenship, 2010, Chemistry & biology.

When overall survival fails to confirm event-free survival, should the latter be used to set the standard of care?

I. Ostrovnaya, S. Roberts, B. Kushner, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic Breakpoint Characterization and Transcriptome Analysis of Metastatic, Recurrent Desmoplastic Small Round Cell Tumor

K. Moroz, N. Cheung, Madelyn Espinosa-Cotton, 2023, Sarcoma.

Clinical progress in neuroblastoma.

N. Cheung, N. Cheung, M. Bonilla, 1994, Cancer investigation.

Clinically critical impact of molecular genetic studies in pediatric solid tumors.

W. Gerald, M. Ladanyi, A. Hamelin, 1999, Medical and pediatric oncology.

Association of CYP3A4 genotype with treatment-related leukemia.

P. Nowell, T. Rebbeck, B. D. Lovett, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review.

S. Jhanwar, G. Heller, B. Kushner, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Promise and Challenges of T Cell Immunotherapy for Osteosarcoma

N. Cheung, Jeong A. Park, 2023, International journal of molecular sciences.

Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.

R. R. Robinson, R. Reisfeld, J. Hank, 1990, Cancer research.

PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma.

N. Volkow, S. Larson, A. Wolf, 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Synovial sarcoma mimicking desmoplastic small round-cell tumor: critical role for molecular diagnosis.

W. Gerald, M. Ladanyi, M. LaQuaglia, 1999, Medical and pediatric oncology.

CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma.

N. Cheung, T. Caragine, S. Tomlinson, 2000, Cancer research.

Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro.

N. Cheung, M. Tykocinski, N. Cheung, 1988, The Journal of clinical investigation.

Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma.

N. Cheung, B. Kushner, N. Cheung, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma.

B. Kushner, K. Kramer, N. Cheung, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.

W. Gerald, S. Larson, B. Kushner, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma.

M. E. Robinson, B. M. Cohen, A. Cnaan, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors.

P. Meyers, B. Kushner, K. Kramer, 2000, Medical and pediatric oncology.

Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma.

N. Cheung, F. Miraldi, N. Cheung, 1987, Cancer research.

PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma

Hong Xu, Hong-fen Guo, N. Cheung, 2019, Blood.

3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.

S. Larson, N. Cheung, S. Yeh, 1998, International journal of oncology.

Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma.

N. Cheung, G. Heller, Hong-fen Guo, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.

W. Gerald, S. Larson, N. Cheung, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival.

S. Larson, N. Cheung, G. Heller, 1994, Cancer research.

Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers.

N. Cheung, N. Cheung, I. Cheung, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeting of ganglioside GD2 monoclonal antibody to neuroblastoma.

N. Cheung, F. Miraldi, N. Cheung, 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Prognostic significance of EPHB6, EFNB2, and EFNB3 expressions in neuroblastoma.

M. E. Robinson, A. Cnaan, N. Cheung, 2000, Medical and pediatric oncology.

Immunotherapy. Neuroblastoma as a model.

N. Cheung, N. Cheung, 1991, Pediatric clinics of North America.

Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors.

S. Gultekin, Hong-fen Guo, K. Kramer, 2001, Cancer research.

GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma.

B. Kushner, N. Cheung, B. Kushner, 1989, Blood.

Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy.

M. LaQuaglia, S. Wolden, S. Roberts, 2023, International journal of cancer.

Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.

S. Larson, H. Yeung, B. Kushner, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of parenteral recombinant human macrophage colony-stimulating factor on monocyte number, phenotype, and antitumor cytotoxicity in nonhuman primates.

D. Munn, N. Cheung, M. Garnick, 1990, Blood.

GD2 oligosaccharide: target for cytotoxic T lymphocytes

N. Cheung, N. Cheung, Xiao-Juan Zhao, 1995, The Journal of experimental medicine.

Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy

C. Klein, N. Cheung, B. Santich, 2020, Frontiers in Oncology.

Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab')2-cobra venom factor conjugate are equally cytotoxic.

H. Juhl, N. Cheung, E. Petrella, 1990, Molecular immunology.

Stage 4N neuroblastoma before and during the era of anti‐GD2 immunotherapy

M. LaQuaglia, S. Wolden, S. Roberts, 2023, International journal of cancer.

Differential expression of genes mapping to recurrently abnormal chromosomal regions characterize neuroblastic tumours with distinct ploidy status

W. Gerald, J. Mora, E. de Álava, 2008, BMC Medical Genomics.

DIFFERENTIATION OF PRESUMED SEPSIS FROM ACUTE GRAFT‐VERSUS-HOST DISEASE BY C‐REACTIVE PROTEIN AND SERUM TOTAL IgE IN BONE MARROW TRANSPLANT RECIPIENTS

H. Lazarus, P. Coccia, N. Cheung, 1987, Transplantation.